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Abstract
Drugs are two-sided swords and statins are no
exception. Schooling et al. demonstrate that, on
average, statins produce small, but statistically
significant, decreases in testosterone. They
appropriately emphasize that the clinical significance
of their observations is unclear but suggest that
changes in testosterone might be related to the
benefits of therapy as well as the risks, such as the
increased chance of diabetes mellitus. Their findings
and hypotheses are noteworthy. However, we believe
this represents another example of the limitations in
the published summaries of drug effects. How do we
know all changes induced by drugs are normally
distributed? Some may be affected much more than
others. Moreover, the confidence intervals of a meta-
analysis describe the variance of the mean effect, not
the range of effects, and while the mean change
characterizes the impact of a drug on a group of
patients, the range more fully characterizes its effects
on individuals. We treat individuals not groups.
Averages do not disclose enough about the risks and
benefits of drugs.
See related research article here http://www.
biomedcentral.com/1741-7015/11/57
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Background
For so long, statins seemed so simple. All the news, or
almost all the news, was good news. However, our con-
fidence, or was it smugness, that we knew all we needed
to know about this important class of drugs has ended
with the recent evidence that diabetes mellitus may be a
side-effect of statin therapy [1], a realization that comes
disappointingly late in the game given how many years
statins have been used and how many statin studies
have been performed; further proof that randomized
clinical trials (RCTs) are better tests of the benefits than
the risks of therapies and that RCTs are only one element
in the full montage of evidence that needs to be
assembled about the benefits and risk of drug therapy.
The present study by Schooling et al. [2] examines
another issue that does not seem to have received the
attention it deserves - do statins lower testosterone and,
if so, could that effect be biologically relevant in terms of
how statins achieve their benefit or, perhaps, represent
another way how they might harm us [2]?
Discussion
Cholesterol is an obligate precursor of sex hormones and
statins inhibit HMG CoA reductase, the rate-limiting
enzyme in the synthesis of cholesterol. In principle, this
should not matter as sufficient cholesterol should be
delivered to these cells by the low-density lipoprotein
(LDL) pathway, the biological alternative to de novo
synthesis. However, this may represent yet another exam-
ple of how real life refuses to conform to our models of it,
since the meta-analysis by Schooling et al. [2] indicates
that this does occur. In men, testosterone was lowered by
doses of statins they describe as typical (but we would
characterize as low to moderate) by about 4% (0.66 mmol/l;
95% CI -0.14 to 1.18) and by about 11% (0.4 mmol/L; 95%
CI -0.05 to 0.76) in women.
Five trials with a total of 501 men and six trials with a
total of 368 women with polycystic ovary syndrome
were analyzed. The decreases were significant for both
fixed and random effects models. The authors identify
several reasons their results may be less compelling in
women. First, funnel plots did suggest some evidence of
publication bias, the assays for testosterone may be less
reliable in women given the lower levels, and no effect was
observed when only the higher quality trials were analyzed.
Moreover, the women were selected for a disorder that
may be related to abnormal androgen metabolism. By con-
trast, in men, there was no evidence of publication bias
and the results were more homogenous and more robust
in that the results in the higher quality studies were the
same as in the overall analysis.
This meta-analysis appears to have been well perfor-
med with a genuine attempt to identify all the relevant
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literature as well as an evaluation of factors that might lead
to a misleading result. The authors note that statins have
been reported to reduce androgens in women with poly-
cystic ovary syndrome and they hypothesize that reduction
of androgens might favorably modulate the immune
response and reduce atherogenesis. They also hypothesize
that lower testosterone levels might be involved in the
genesis of the increased risk of diabetes mellitus. However
interesting and potentially important these issues are,
attention will, doubtless, also focus on whether lower
testosterone levels might alter sexual drive and function
in men.
Nevertheless, are the findings clinically significant? As
the authors fairly point out, a definitive answer is not
easy. The average changes are small, the range of nor-
mal values for testosterone wide, and there is no clear
relation between testosterone concentration and sexual
drive and function. Moreover, the clinical information
linking statins to sexual dysfunction is extremely limited
[3,4]. Accordingly, it would be easy to dismiss the obser-
vations as statistically, but not clinically, significant.
However, we believe the real lesson to be learned is how
inadequately we measure and report the effects of drugs
and this directly limits our ability to fully understand
their myriad effects.
By convention, the effects of drugs in meta-analysis are
expressed as a summary geometric mean and confidence
interval. But what evidence supports this convention and
why should we assume that it holds for all the effects of
a drug? And even if it does, there can be considerable
variance in the response to a drug. As illustrated in the
JUPITER trial (Justification for the Use of Statins in
Primary Prevention: an Intervention Trial Evaluating
Rosuvastatin), the lowering of LDL cholesterol (C) by a
statin, in this case 20 mg rosuvastatin, is highly variable
with 10% of subjects having <20% and 10% >70% decrease
in LDL C [5]. The absolute benefit of a statin depends on
the absolute lowering of LDL C, which is determined by
the initial level of LDL C as well as the potency and dose of
the statin [6]. Therefore, the benefits of statins depend on
to whom they are given as well as their intrinsic potency.
The lesson should be that it is the actual response of a
specific patient to an agent that should concern us, not the
average response of a group of patients.
This meta-analysis is, necessarily, based on the data as
originally reported, which are restricted to the average
decrease observed with statins. It is important to appreci-
ate that the 95% confidence intervals reported refer only
to variance in the average effect size not, as is commonly
thought, to the range of possible outcomes. There is,
of course, no a priori reason why there might not be sub-
stantial dispersion of such decreases in testoster-
one induced by rosuvastatin just as there is for LDL C
lowering, in which case, more extreme changes in plasma
testosterone level will occur in an important number of
people who take statins. If so, notwithstanding that the
average reductions in testosterone in groups of individuals
are small, more extreme decreases in testosterone in cer-
tain individuals might explain part of the benefits (or
risks) of statin therapy. Alternatively, the dispersion may
be much less; the effect much more uniform. Our point is
that the answer to this ‘clinical’ question is in the data, the
actual data and not the summary calculations of the data.
Conclusion
In this first meta-analysis of the issue, Schooling et al.
[2] report that statins lower serum testosterone in both
men and women, a potentially important finding. Unfor-
tunately, the clinical implications of this observation are
less clear than they could be because the only data avail-
able to them were the average changes in testosterone
induced by statins. While the average changes may be
small, the range of changes in individuals, potentially,
might be much more substantial. The problem is that
we have become accustomed to expressing the effects of
our therapies in terms of the average changes in groups
as opposed to also considering the range of changes in
individuals. We need to acknowledge this shortcoming
if we are going to learn more about the benefits and
risks of drugs and really understand whether side effects,
as reported by Schooling et al., truly matter.
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